Prospective Clinical Study To Evaluate The Efficacy And Safety Of An Alexandrite Laser Device For The Treatment Of Acne Scars
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 39
- 试验地点
- 4
- 主要终点
- Photographic Evaluation of Changes in Treatment Areas
研究概览
简要总结
The intended use of the Alexandrite laser device used in this study is to assess the efficacy and safety of the Alexandrite laser device for the treatment of acne scars on skin types V and VI.
详细描述
Subjects are to be enrolled in this clinical study if they are 18-65 years old. A maximum of 25 subjects will be enrolled at 1 study center. Subjects will receive up to 6 treatments (minimum of 4 treatment visits with an optional 5th and 6th treatment) on the face. Subjects will return for follow up visits at 30 and 90 days post last treatment. All subjects will receive a phone call 1 week after each treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •A healthy male or female 18 - 65 years of age.
- •Has acne scars on the face (left, right, or front) and willing to undergo treatments with the study device.
- •Is a skin type V or VI.
- •Understands and accepts obligation not to receive any other procedures on the treatment area through the length of the study.
- •Understands and accepts the obligation and is logistically able to be present for all visits.
- •Is willing to comply with all requirements of the study and sign the informed consent document.
排除标准
- •Is pregnant or of childbearing potential and not using medically effective birth control, or has been pregnant in the last 3 months, currently breast feeding or planning a pregnancy during the study.
- •The subject is hypersensitive to light in the near infrared wavelength region.
- •The subject takes medication which is known to increase sensitivity to sunlight.
- •The subject has seizure disorders triggered by light.
- •The subject takes or has taken oral isotretinoin, such as Accutane®, within the last six months.
- •The subject has an active localized or systemic infection, or an open wound in area being treated.
- •The subject has a significant systemic illness, such as lupus, or an illness localized in area being treated.
- •The subject has common acquired nevi that are predisposed to the development of malignant melanoma.
- •The subject has herpes simplex in the area being treated.
- •The subject is receiving or has received gold therapy.
- •The subject is currently enrolled in an investigational drug or device trial, or has received an investigational drug or been treated with an investigational device within in the area to be treated 6 months to entering this study.
- •The subject has any condition or is in a situation which in the investigators opinion may put the subject at significant risk, may confound study results or may interfere significantly with the subject's participation.
- •Cautionary Criteria:
- •The subject has had unprotected sun exposure within four weeks of treatment, including the use of tanning beds or tanning products, such as creams, lotions and sprays.
- •The subject has a history of immunosuppression/immune deficiency or an auto-immune disorder.
- •The subject has a coagulation disorder or currently using anticoagulation medication, including heavy use of aspirin.
- •The subject is taking medications that alter the wound-healing response or evidence of compromised wound healing.
- •The subject is known to have a history of keloid formation.
- •The subject has a history of skin cancer or suspicious lesions in the treatment area.
结局指标
主要结局
Photographic Evaluation of Changes in Treatment Areas
时间窗: Baseline and 90 day follow up
Photographic evaluation with ECCA (échelle d'évaluation clinique des cicatrices d'acné) grading comparing pre-treatment images to the 90 day follow up images performed by independent reviewers. This scale gives higher scores based on the number of scars, with the description of the scars determining the weighting factor. The scale ranges from 0 to 540, with a lower score meaning less severe scarring.
次要结局
- Subject satisfaction(90 day follow up)
- Photographic Evaluation of Treatment Areas(Baseline and 30 day follow up)
- Blinded evaluation of pre-treatment images vs. follow up images to determine which image is which(Baseline and 90 day follow up)
- Subject assessment using the Global Aesthetic Improvement Scale (SGAIS)(Baseline and 90 day follow up)
- Principle Investigator assessment using the Global Aesthetic Improvement Scale (PGAIS)(Baseline and 90 day follow up)